Login

Journal Image
Current Pharmaceutical Design
ISSN (Print): 1381-6128
ISSN (Online): 1873-4286
VOLUME: 8
ISSUE: 25
DOI: 10.2174/1381612023393125      Price:  $58









Design and Discovery of Small Molecules Targeting Raf-1 Kinase

img
Author(s): Timothy B. Lowinger, Bernd Riedl, Jacques Dumas and Roger A. Smith
Pages 2269-2278 (10)
Abstract:
Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation. Thus, small molecule inhibitors of Raf kinase activity may be important agents for the treatment of cancer. A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chemistry approaches. This effort culminated in the identification of the clinical candidate BAY 43-9006, currently undergoing Phase I clinical trials. The present review summarizes the medicinal chemistry development of ureas as highly potent inhibitors of Raf-1 kinase.
Keywords:
diphenyl ureas, bay 43-9006, raf-1 kinase, cancer, ras
Affiliation:
Bayer AG, Pharma Research Center, D-42096, Wuppertal, Germany